Teladoc Health Partners With Eli Liily's LillyDirect to Expand Access to Zepbound For Weight Loss

Telemedicine operator Teladoc Health Inc TDOC has entered a pharmacy integration agreement with Eli Lilly And Co's LLY LillyDirect, a direct-to-consumer pharmacy partner, to streamline access to Zepbound (tirzepatide) for members of Teladoc's Comprehensive Weight Care Program.

Last year, Eli Lilly announced a new website allowing patients to get a prescription for weight loss through a telehealth provider, marking an industry first.

The collaboration aims to provide affordable and safe options for individuals without insurance coverage for GLP-1 medications used for obesity treatment.

Under the agreement, eligible Teladoc Health members prescribed Zepbound by their provider will have the medication delivered directly to their homes via LillyDirect's digital healthcare platform.

Also Read: Teladoc Stock Gains As Amazon Partnership Fuels Push for Consumer-Centric Healthcare

Teladoc's Comprehensive Weight Care and Primary360 teams will have full visibility into each stage of the fulfillment process, including dispensing, shipping, delivery, and refills.

Beyond medication access, Teladoc's Comprehensive Weight Care Program offers a multi-disciplinary approach to obesity management. Members receive support from licensed clinicians with specialized training in obesity medicine, registered dietitians, and health coaches.

Novo Nordisk A/S NVS recently introduced NovoCare Pharmacy, a direct-to-patient delivery service to improve access to Wegovy (semaglutide) for cash-paying patients.

In February, Teladoc reported fourth-quarter revenue of $640.5 million, down 3% year over year, almost in line with the consensus estimates.

Price Action: TDOC stock is up 8.02% at $9.75 at the last check Thursday.

Read Next:

• Target Hospitality Secures Five-Year Lease With CoreCivic For Dilley Facility, Stock Gains

Photo by Ciara Kimsey via Shutterstock